Pier Capital LLC Boosts Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Pier Capital LLC boosted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,642 shares of the medical instruments supplier’s stock after acquiring an additional 53 shares during the period. Pier Capital LLC’s holdings in West Pharmaceutical Services were worth $541,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of WST. Fidelis Capital Partners LLC bought a new position in West Pharmaceutical Services during the first quarter valued at $27,000. Crewe Advisors LLC lifted its position in West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 71 shares during the last quarter. Quarry LP lifted its position in West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services during the first quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services during the first quarter valued at $40,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

WST stock opened at $302.35 on Thursday. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $306.18 and a two-hundred day simple moving average of $340.02. The firm has a market capitalization of $22.02 billion, a P/E ratio of 39.89, a price-to-earnings-growth ratio of 10.60 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. West Pharmaceutical Services’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.11 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Transactions at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.